The U.K. authorizes AstraZeneca's coronavirus vaccine for emergency supply

The first authorization of its vaccine could be the only green light it receives for several months.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

On Wednesday morning, the U.K. authorized AstraZeneca's (NASDAQ: AZN) coronavirus vaccine candidate for emergency supply. The first doses of COVID-19 Vaccine AstraZeneca (formerly known as AZD1222) will be released today with the intention to begin vaccinations early in the new year.

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) recommends two full doses given four to 12 weeks apart. This is the dosing regimen that appeared 62% effective in clinical trials in the U.K. and Brazil.

You may remember an unintentionally administered half-dose/full-dose regimen that appeared more than 90% effective in a smaller group of patients. Unfortunately, data available to the MHRA wasn't sufficient to persuade the agency to deviate from the two full doses received by the vast majority of clinical trial participants.

The European Medicines Agency (EMA) and the Food and Drug Administration aren't on the same page as the MHRA. As a result, timelines for similar authorizations for AstraZeneca are still fuzzy. 

On Tuesday, EMA executive director Noel Wathion told reporters that AstraZeneca hasn't even filed an application yet. While AstraZeneca has sent in some data, it hasn't been enough to warrant a conditional marketing license.

In the U.S., COVID-19 Vaccine AstraZeneca's path forward is going to be bumpy. The company's CEO has hinted at more-compelling clinical trial data to come, but the results we've seen so far don't meet the FDA's pre-determined efficacy threshold. Plus, the FDA has clearly stated it's unwilling to authorize a candidate without some pivotal data from a U.S. study. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A woman sits at her desk thinking. She is surrounded by projections of world maps on various screens with data appearing below them.
International Stock News

A clear case for international investing

US shares have outperformed Australian shares by a wide margin over the past 30 years.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
International Stock News

Prediction: Nvidia's recent unobtrusive maneuver could signal a big growth move ahead.

Let's take a look.

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
International Stock News

Prediction: This artificial intelligence (AI) stock could be the next Nvidia — and it's not what you think

Let's take a closer look at that name and see why it could turn out to be a solid addition…

Read more »

A woman in jeans and a casual jumper leans on her car and looks seriously at her mobile phone while her vehicle is charged at an electic vehicle recharging station.
International Stock News

Worried about Tesla's Robotaxi? These two words from Nvidia CEO Jensen Huang might change your mind.

Investors are on the edge of their seats as Tesla's robotaxi launch is reportedly around the corner.

Read more »

AI written in blue on a digital chip.
International Stock News

Warren Buffett has 23% of Berkshire Hathaway's portfolio invested in 2 AI stocks up 600% and 900% in the last decade

Here's what investors should know about these two stocks.

Read more »

Happy woman working on a laptop.
International Stock News

Want to invest in quantum computing? 3 stocks that are great buys right now.

They all give investors direct exposure to quantum computing, but aren't the all-or-nothing bets that some investors may regret going…

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Billionaire Dan Loeb just sold Meta and Tesla stocks and piled into this hot AI stock up 1,500% over the past 5 years

Let's see what investors are thinking about these stocks today.

Read more »

A head shot of legendary investor Warren Buffett speaking into a microphone at an event.
International Stock News

Warren Buffett just spent $1.8 billion on 7 stocks. Here's the best of the bunch

Buffett's relatively small investments could be big opportunities for individual investors.

Read more »